Header Logo

Connection

Mary Rusckowski to Neoplasms

This is a "connection" page, showing publications Mary Rusckowski has written about Neoplasms.
Connection Strength

0.674
  1. Ramesh K, Truong A, Wang Y, Rusckowski M, Gkikas M. Ligand-Specific Nano-Contrast Agents Promote Enhanced Breast Cancer CT Detection at 0.5 mg Au. Int J Mol Sci. 2022 Sep 01; 23(17).
    View in: PubMed
    Score: 0.094
  2. Clear KJ, Harmatys KM, Rice DR, Wolter WR, Suckow MA, Wang Y, Rusckowski M, Smith BD. Phenoxide-Bridged Zinc(II)-Bis(dipicolylamine) Probes for Molecular Imaging of Cell Death. Bioconjug Chem. 2016 Feb 17; 27(2):363-75.
    View in: PubMed
    Score: 0.058
  3. Dou S, Smith M, Wang Y, Rusckowski M, Liu G. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy. Cancer Biother Radiopharm. 2013 May; 28(4):335-42.
    View in: PubMed
    Score: 0.049
  4. Liu G, Dou S, Liu Y, Wang Y, Rusckowski M, Hnatowich DJ. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug Chem. 2011 Dec 21; 22(12):2539-45.
    View in: PubMed
    Score: 0.044
  5. Chen L, Wang Y, Cheng D, Dou S, Liu X, Liu G, Hnatowich DJ, Rusckowski M. Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents. Nucl Med Commun. 2011 Oct; 32(10):920-4.
    View in: PubMed
    Score: 0.044
  6. Liu Y, Cheng D, Liu X, Liu G, Dou S, Xiao N, Chen L, Rusckowski M, Hnatowich DJ. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation. Nucl Med Biol. 2012 Jan; 39(1):101-7.
    View in: PubMed
    Score: 0.044
  7. Cheng D, Rusckowski M, Wang Y, Liu Y, Liu G, Liu X, Hnatowich D. A brief evaluation of tumor imaging in mice with 99mTc-glucarate including a comparison with 18F-FDG. Curr Radiopharm. 2011 Jan; 4(1):5-9.
    View in: PubMed
    Score: 0.042
  8. Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
    View in: PubMed
    Score: 0.042
  9. Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, Rusckowski M, Hnatowich DJ. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem. 2010 Jul 21; 21(7):1385-8.
    View in: PubMed
    Score: 0.040
  10. Liang M, Liu X, Cheng D, Nakamura K, Wang Y, Dou S, Liu G, Rusckowski M, Hnatowich DJ. Optical antisense tumor targeting in vivo with an improved fluorescent DNA duplex probe. Bioconjug Chem. 2009 Jun; 20(6):1223-7.
    View in: PubMed
    Score: 0.037
  11. Liu X, Wang Y, Nakamura K, Kawauchi S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J Nucl Med. 2009 Apr; 50(4):582-90.
    View in: PubMed
    Score: 0.037
  12. Liu X, Wang Y, Nakamura K, Liu G, Dou S, Kubo A, Rusckowski M, Hnatowich DJ. Optical antisense imaging of tumor with fluorescent DNA duplexes. Bioconjug Chem. 2007 Nov-Dec; 18(6):1905-11.
    View in: PubMed
    Score: 0.033
  13. Liu G, Dou S, Yin D, Squires S, Liu X, Wang Y, Rusckowski M, Hnatowich DJ. A novel pretargeting method for measuring antibody internalization in tumor cells. Cancer Biother Radiopharm. 2007 Feb; 22(1):33-9.
    View in: PubMed
    Score: 0.032
  14. He J, Rusckowski M, Wang Y, Dou S, Liu X, Zhang S, Liu G, Hnatowich DJ. Optical pretargeting of tumor with fluorescent MORF oligomers. Mol Imaging Biol. 2007 Jan-Feb; 9(1):17-23.
    View in: PubMed
    Score: 0.032
  15. Zhang YM, Wang Y, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA. J Nucl Med. 2001 Nov; 42(11):1660-9.
    View in: PubMed
    Score: 0.022
  16. Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
    View in: PubMed
    Score: 0.009
  17. Hnatowich DJ, Gionet M, Rusckowski M, Siebecker DA, Roche J, Shealy D, Mattis JA, Wilson J, McGann J, Hunter RE, et al. Pharmacokinetics of 111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody. Cancer Res. 1987 Nov 15; 47(22):6111-7.
    View in: PubMed
    Score: 0.008
  18. Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, Shealy D, Doherty PW. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med. 1985 Aug; 26(8):849-58.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.